Age ≥ 65 years and leukocytosis ≥ 15 G / l are factors that increase the risk of thrombosis in patients with ET; Patients with CALR gene mutations, low and intermediate - 1 risk group, Hb 80 g / l is a factor that increases overall survival in PMF patients.